IP Library Granted Patent US 7,820,667
Granted Patent B2
US 7,820,667 · App. 11/209,673 · Granted Oct 26, 2010

Methods of treating hypertension

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,820,667
App. No.
11/209,673
Granted
Oct 26, 2010
Kind
B2
Abstract

It is an object of the present invention to provide a therapeutic agent for effectively preventing or ameliorating diseases caused by dysfunction of NOS. The present invention provides a pharmaceutical composition for preventing and/or treating diseases associated with dysfunction of NOS, comprising as an effective ingredient, a compound of the formula (I): wherein R 1 and R 2 each represents a hydrogen atom or, taken together with each other, represent a single bond, while R 3 represents —CH(OH)CH(OH)CH 3 , —CH(OCOCH 3 )CH(OCOCH 3 )CH 3 , —CH 3 , —CH 2 OH, or a phenyl group when R 1 and R 2 each represents a hydrogen atom, or —COCH(OH)CH 3 when R 1 and R 2 together represent a single bond, or a pharmaceutically acceptable salt thereof.

Claims (6)

1. A method of treating hypertension comprising:

administering for at least 4 weeks to a patient in need of such treatment, a therapeutically effective amount of a compound of the formula (I):

wherein R 1 and R 2 each represents a hydrogen atom, and R 3 represents —CH(OH)CH(OH)CH 3 , or a pharmaceutically acceptable salt thereof, and wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a dose range of 0.1 to 50 mg/kg(b.w.)/day.

2. The method of treating hypertension according to claim 1 , wherein R 3 of the formula I is L-erythro-CH(OH)CH(OH)CH 3 .

3. The method of treating hypertension according to claim 1 or 2 , wherein hypertension is selected from a group consisting of pulmonary hypertension, portal hypertension, essential hypertension, renal hypertension, renovascular hypertension, pregnancy-induced hypertension, senile hypertension and adrenal hypertension.

4. The method of treating hypertension according to claim 1 or 2 , wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is administered in a dose range of 0.5 to 10 mg/kg(b.w.)/day.

Assignments (5)
CHANGE OF NAME Recorded Aug 18, 2010
From: DAIICHI SUNTORY PHARMA CO., LTD.
To: DAIICHI ASUBIO PHARMA CO., LTD.
Reel/Frame 024853/0444 →
MERGER Recorded Jun 28, 2010
From: ASUBIO PHARMA CO., LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 024605/0766 →
CHANGE OF NAME Recorded Apr 26, 2007
From: DAIICHI ASUBIO PHARMA CO. LTD.
To: ASUBIO PHARMA CO., LTD.
Reel/Frame 019236/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2005
From: SUNTORY LIMITED
To: DAIICHI SUNTORY PHARMA CO., LTD.
Reel/Frame 017360/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2005
From: ISHIHARA, TAKAFUMI; KANAYAMA, YOSHIHARU; OKAMURA, MIKIO; YOSHIKAWA, JUNICHI; SHINTAKU, HARUO
To: SUNTORY LIMITED
Reel/Frame 016921/0828 →